Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interleukin-1-alpha
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-23 of 23 for your search:
Start Over
Phase I/II Study of IL-1A/MITO with Ketoconazole for Metastatic Colorectal and Prostate Carcinomas (Summary Last Modified 08/95)
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CRB-9202, NCI-T94-0090N, T94-0090
Phase I/II Study of IL-1A plus ICE (IFF/CBDCA/VP-16) with Autologous Bone Marrow Transplantation with and without G-CSF in Patients with Metastatic Carcinomas and Lymphomas (Summary Last Modified 03/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: NCI
Protocol IDs: NCI-91-C-0156B, NCI-MB-273, NCI-T91-0090N, T91-0090
Phase II Study of IL-1A/VP-16 in Relapsed Osteosarcoma (Summary Last Modified 12/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 5 to 70
Sponsor: NCI
Protocol IDs: MDA-P-93003, NCI-T93-0163D, T93-0163
Phase II Evaluation of IL-1A, Indomethacin, and VP-16 in Patients with Metastatic Malignant Melanoma
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CRB-9001C, NCI-90-C-83C, NCI-T89-0239N, T89-0239
Phase II Randomized Study to Evaluate the Hematopoietic Effect of IL-1A on Granulothrombocytopenia Associated with Hemibody Irradiation
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9206, RTOG-92-06
Phase I Study of IL-1A/MTX in Patients with Advanced Solid Tumors (Summary Last Modified 02/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BWH-92-5440-01, NCI-T93-0188O, T93-0188
Phase I Study of IL-1A/CBDCA for Advanced Solid Tumors (Summary Last Modified 04/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BWH-92-5232-02, NCI-T93-0187O, T93-0187
Phase I Study of IL-1A/DTIC in Patients with Solid Tumors (Summary Last Modified 05/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BWH-T92-0254, NCI-T92-0254O, T92-0254
Phase I Study of IL-1A/CTX in Patients with Advanced Solid Tumors (Summary Last Modified 04/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: PCI-9341, NCI-T93-0135D, T93-0135
Phase I Evaluation of Interleukin-1-alpha in Patients with Solid Tumors
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: BRMP-8808B, NCI-89-C-84B, NCI-T88-0246N, T88-0246
Phase I Study of Intratumoral Interleukin-1-alpha (Summary Last Modified 05/92)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-9002A, NCI-90-C-220A, NCI-T90-0085N, T90-0085
Phase I Study of High-Dose CBDCA/IL-1A in Advanced Nonsmall Cell Lung Cancer and Other Advanced Malignancies (Summary Last Modified 08/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CRB-8921A, NCI-90-C-222A, NCI-T90-0018N, T90-0018
Phase I Study of Recombinant IL-1A and IL-2 in Patients with Advanced Melanoma, Renal Cell Cancer, or Lymphoma (Summary Last Modified 06/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-6190, NCI-T91-0087C, T91-0087
Phase I Study of IL-1A with and without Indomethacin for Solid Tumors and Lymphoma (Summary Last Modified 03/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: TTUHSC-M-1078, NCI-T91-0078O, T91-0078
Phase I Study of IL-1A/MTX in Patients with Solid Tumors (Summary Last Modified 02/92)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BWH-T91-0101, NCI-T91-0101D, T91-0101
Phase I Study of IL-1A/CBDCA in Patients with Solid Tumors (Summary Last Modified 03/93)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and older
Sponsor: NCI
Protocol IDs: BWH-T91-0103, NCI-T91-0103D, T91-0103
Phase I Study of IL-1A to Ameliorate CTX-Induced Myelosuppression in Patients with Advanced Cancers (Summary Last Modified 03/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: EST-PX-990, EST-P-X990
Phase I Study of Adjuvant IL-1A Immunotherapy with an Allogeneic Colon Cancer Vaccine for Dukes' D Colon or Rectal Cancer (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 to 100
Sponsor: NCI
Protocol IDs: URCC-4290M, NCI-T91-0094D, T91-0094
Phase I Study of Autologous Bone Marrow Transplant of Marrow-Treated IL-1A/TNF/4-HC in Patients with High-Risk AML in Second Remission (Summary Last Modified 06/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 15 to 55
Sponsor: NCI
Protocol IDs: UF-T91-0273, NCI-T91-0273O, T91-0273
Phase I Study of Methylene Blue for the Treatment of Hypotension in Patients with Advanced Cancer Receiving IL-1A Support for CBDCA
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: BRMP-9211, NCI-T92-0216N, T92-0216
Phase IB Study of IL-1A/CDDP in Patients with Metastatic Melanoma (Summary Last Modified 05/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-9201, NCI-B92-0015, B92-0015
Phase I Study of IL-1A/CBDCA in Patients with Metastatic Disease (Summary Last Modified 08/95)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PCI-9280, NCI-T94-0017D, T94-0017
Start Over